(Adnkronos) - “Tezepelumab rappresenta un approccio pionieristico di AstraZeneca nell’andare a targettizzare il Tlsp come citochina epiteliale a monte della cascata infiammatoria. Questa nuova molecola ha già dimostrato di essere estremamente efficace e sicura nell’ambito dell’asma grave e, da oggi, grazie anche ai risultati dello studio Waypoint, sappiamo essere altrettanto efficace e sicura anche nei soggetti affetti da rinosinusite cronica con poliposi nasale”. Lo afferma Raffaela Fede, direttore medico di AstraZeneca Italia, in occasione dell’incontro organizzato a Milano sui risultati dello studio di fase 3 Waypoint sull’anticorpo monoclonale tezepelumab, già approvato e rimborsato in Italia per il trattamento dell’asma grave non controllato.
Category
🗞
NewsTranscript
00:00Astrazeneca is always committed to research and development, especially in the field of
00:10respiratory and immunological pathologies. Tezepelumab represents a pioneering approach
00:17of Astrazeneca in targeting TSLP as an epithelial cytokine on the brink of a
00:26inflammatory cascade. This new molecule has already proven to be extremely effective and
00:33safe in the field of severe asthma and today, thanks also to the results of the Waypoint study,
00:38we know how to be just as effective and safe also in subjects affected by chronic rhinosinusitis
00:46with nasal polyposis. This is certainly an important milestone for us that we can
00:55progress in our research and development of new therapeutic targets in the field of
01:01respiratory and immunological precision medicine. In fact, we have a great investment in research,
01:08both globally and especially in Italy. We have 28 active clinical studies throughout
01:14our national territory and we have the first major study of Real World Evidence,
01:21which will assess the effectiveness of Tezepelumab in 35 Italian centers on over
01:30300 subjects affected by severe asthma and also with chronic rhinosinusitis and nasal polyposis.
01:37The results of the Waypoint study, which was designed to assess the effectiveness and
01:42safety of Tezepelumab in the treatment of adult subjects affected by chronic rhinosinusitis
01:49with nasal polyposis, have already been published in the New England Journal of Medicine precisely
01:55for the impact they have on subjects affected by this pathology. In fact, the study has shown
02:01to significantly reduce the size of polyps and nasal congestion in these subjects and
02:08the associated burden of the presence of polyps, reducing 98% the need to go
02:17for a surgical intervention and, just as important, in 88% of cases, the reduction of the use of
02:25oral corticosteroids, which we know is certainly one of the issues for which we aim to treat
02:34these subjects with biological drugs, also reducing the complications induced by the steroid.